Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Korean Association for the Study of Intestinal Diseases 2022-01-01
Edice:	Intestinal Research
Témata:	vedolizumab ulcerative colitis surgical complications crohn disease inflammatory bowel disease
On-line přístup:	http://irjournal.org/upload/pdf/ir-2020-00117.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!